Images (2)

Doxorubicin

Author:Prof. Dr. med. Peter Altmeyer

Last updated on: 14.02.2022

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Substance from the group of cytostatic drugs (anthracyclines).

Half-lifeThis section has been translated automatically.

30–33 h

IndicationThis section has been translated automatically.

Lymphomas, leukemias, solid tumors; Kaposi's sarcoma.

Dosage and method of useThis section has been translated automatically.

40-75 mg/m2 KO i.v. every 3-4 weeks Maximum cumulative dose 550 mg/m2 KO.

Notice! Under therapy and up to 3 months afterwards, women and men must practice effective contraception!

Undesirable effectsThis section has been translated automatically.

Dermatologic complications:

Alopecia
Pruritus
Reactions at the infusion site
Exanthema
Flush
Onycholysis
Nail pigmentation
Phlebitis
Stomatitis(mucositis)
Rarely urticaria (depending on source: 0.01-3% of pat.)

Other:

Gastrointestinal disorders
Liver damage
Hyperuricemia
Spermatogenesis and ovulation disorders
Hematopoiesis disorders
Cardiotoxicity (cardiomyopathy).

InteractionsThis section has been translated automatically.

See Table 1.

ContraindicationThis section has been translated automatically.

Pregnancy, nursing.

PreparationsThis section has been translated automatically.

Adriblastine, DOXO-cell, Doxorubicin, Ribodoxo-L

LiteratureThis section has been translated automatically.

Lybaek D et al (2006) Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm Venereol 86: 545-547

TablesThis section has been translated automatically.

Main interactions of Doxorubicin

Acetylcysteine	Cardiotoxicity ↓
Anthracyclines	Cardiotoxicity ↑
Antihistamines	Cardiotoxicity ↓
Cyclophosphamide	Cardiotoxicity ↑
Cytarabine	Intestinal necrosis
Digoxin	Cardiotoxicity ↓
Phenobarbital	Doxorubicin effect ↓
Verapamil	Cardiotoxicity ↓

Authors

Last updated on: 14.02.2022

Author: Prof. Dr. med. Peter Altmeyer